Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Danuglipron
Overview
Danuglipron is an oral, non-peptide small-molecule agonist of the GLP-1 receptor developed to provide convenient daily dosing for type 2 diabetes and obesity. It mimics the effects of endogenous GLP-1 by enhancing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying.
Mechanism of Action
The small-molecule structure enables oral bioavailability without the need for injection.
Research Summary & Key Findings
Phase 2 studies in type 2 diabetes showed dose-dependent reductions in HbA1c and body weight, with data presented at diabetes conferences in 2022 and 2023. Gastrointestinal tolerability challenges were noted, prompting evaluation of modified dosing regimens. Further clinical development is ongoing to optimize therapeutic benefit and adherence.
Clinical Status
Danuglipron is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Danuglipron"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Danuglipron"
Registered interventional and observational studies, including status and phase.
- PubChem: "Danuglipron"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Metabolic
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...
View detailsTirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...
View detailsRetatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...
View detailsAOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...
View detailsNo lawful pathway today
Danuglipron is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.